• HIV-1 Induces DNA Damage Susceptibility in Brain Pericytes

  2026-05-09

  This study reveals that HIV-1 infection impairs DNA damage response in brain vascular pericytes, increasing their vulnerability to extracellular glutamate and neuroinflammatory stimuli. The findings provide new insights into how HIV-associated neuroinflammation compromises blood-brain barrier integrity and highlight experimental models for DNA repair research.

• T7 RNA Polymerase: Recombinant Enzyme Expressed in E. coli

  2026-05-08

  T7 RNA Polymerase is a recombinant enzyme expressed in E. coli with high specificity for T7 promoter-driven in vitro transcription. It enables efficient RNA synthesis from linearized plasmid templates, supporting applications in RNA vaccine production and RNAi research. APExBIO’s K1083 formulation delivers benchmark performance for demanding molecular biology workflows.

• Ruxolitinib (INCB018424): A Selective JAK1/2 Inhibitor for R

  2026-05-08

  Ruxolitinib (INCB018424) is a potent, highly selective ATP-competitive inhibitor of JAK1 and JAK2, widely used in myeloproliferative disorder research. It demonstrates nanomolar potency, robust selectivity, and reproducible inhibition of JAK/STAT pathway signaling in cellular and animal models.

• Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe): Technical

  2026-05-07

  Angiotensin II is a potent vasopressor peptide used to experimentally model hypertension, vascular remodeling, and smooth muscle hypertrophy in cardiovascular research. This technical guide summarizes best practices for preparing, dosing, and storing Angiotensin II for in vitro and in vivo workflows. Not recommended for diagnostic or therapeutic use.

• CDK9 Inhibitor (A3294): Technical Guidance and Protocol Para

  2026-05-07

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for precise suppression of CDK9 activity in transcription elongation and HIV-1 propagation studies. It is not suitable for protocols requiring broad CDK inhibition or long-term storage of working solutions.

• Phillygenin Suppresses Inflammation and Apoptosis in Diabeti

  2026-05-06

  This study demonstrates that phillygenin, a bioactive compound from Forsythia suspensa, attenuates diabetic nephropathy by regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling. The findings highlight its potential as a novel therapeutic agent and provide mechanistic insight into its anti-inflammatory and anti-apoptotic effects.

• X-press Tag Peptide: Precision N-terminal Leader for Protein

  2026-05-06

  X-press Tag Peptide by APExBIO accelerates recombinant protein workflows with its high solubility, robust N-terminal leader design, and compatibility with both affinity purification and antibody-based detection. Grounded in recent mechanistic advances in neddylation and mTORC1 signaling, it enables rigorous, reproducible purification even for complex targets.

• Gly-Gly-Phe-Gly (GGFG): Linker Engineering and Bioconjugatio

  2026-05-05

  Explore how Gly-Gly-Phe-Gly (GGFG) transforms bioconjugation chemistry. This article uniquely examines GGFG peptide’s mechanistic flexibility, practical assay parameters, and structural insights for advanced drug conjugation research.

• AO/PI Double Staining Kit: Practical Guide for Cell Viabilit

  2026-05-05

  The AO/PI Double Staining Kit provides a rapid, reliable means to distinguish viable, apoptotic, and necrotic cells using fluorescent dyes. It is optimized for cell viability, apoptosis, and necrosis detection in diverse research contexts, but should not be used where quantitative live/dead cell enumeration or advanced mechanistic insight beyond viability/apoptosis/necrosis is required.

• TH287 MTH1 Inhibitor: Precision Control of DNA Damage Respon

  2026-05-04

  Discover how the TH287 MTH1 inhibitor advances cancer research by enabling precise experimental control over oxidative DNA damage and radiosensitization, with a focus on rigorous protocol optimization and unique mechanistic insights.

• Pepstatin A: Aspartic Protease Inhibition in Necroptosis Res

  2026-05-04

  Explore the unique utility of Pepstatin A as an aspartic protease inhibitor in dissecting the lysosomal membrane permeabilization process during necroptosis. This article delivers fresh mechanistic insights, advanced protocol guidance, and direct relevance for researchers studying regulated cell death.

• Localized Muscle BDNF and MMPs Direct Early NMJ Postsynaptic

  2026-05-03

  This study uncovers how muscle-derived BDNF, via spatially regulated trafficking and activity-dependent release, controls the earliest formation of acetylcholine receptor clusters at neuromuscular junctions. The work highlights the critical role of proteolytic BDNF conversion—specifically implicating MMPs—in orchestrating synaptic architecture, providing mechanistic and methodological foundations for future experimental targeting.

• TH287 MTH1 Inhibitor: Precision Tools for Cancer Cell Radios

  2026-05-02

  Explore the unique mechanism and advanced applications of the TH287 MTH1 inhibitor in cancer research. This article delivers in-depth scientific analysis and practical guidance on leveraging TH287 for selective radiosensitization, highlighting its distinct role compared to other approaches.

• Arachidonic Acid Enhances Vaccine-Induced Humoral Immunity i

  2026-05-01

  This study demonstrates that dietary arachidonic acid (ARA) supplementation accelerates and enhances the humoral immune response to rabies vaccination in both mice and humans. Mechanistic insights reveal ARA's role in modulating B cell activation via prostaglandin I2, highlighting nutritional modulation as a potential strategy to improve vaccine efficacy.

• Branched Endosomal Disruptor Lipids Advance mRNA Delivery in

  2026-05-01

  The referenced study introduces a new class of branched ionizable lipids (BEND) that enhance endosomal escape, enabling more efficient delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes into hepatic cells and T cells. These findings provide a significant advance in the optimization of lipid nanoparticle (LNP) design for gene editing and mRNA-based therapies, with important implications for both basic research and clinical translation.

15613 records 1/1041 page Next 12345 下5页 Last page